المؤلفون: Claudia C. V. Lang, Egle Ramelyte, Reinhard Dummer

المصدر: Frontiers in Oncology, Vol 10 (2020)

مصطلحات موضوعية: CBCL, radiotherapy, T-VEC, dacetuzumab, bruton thyrosine kinase, intralesional interferon alpha, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2020.01163/full; https://doaj.org/toc/2234-943X

URL الوصول: https://doaj.org/article/f2302bae8e2044cd956fb448550209b1

المؤلفون: Genentech, Inc.

المصدر: A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Fayad L, Ansell SM, Advani R, Coiffier B, Stuart R, Bartlett NL, Forero-Torres A, Kuliczkowski K, Belada D, Ng E, Drachman JG. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015;56(9):2569-78. doi: 10.3109/10428194.2015.1007504. Epub 2015 Feb 26.

المؤلفون: Genentech, Inc.

المصدر: A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol. 2014 Jun 12;7:44. doi: 10.1186/1756-8722-7-44.

المؤلفون: Genentech, Inc.

المساهمون: Jonathan Drachman, Sr. Medical Director

المصدر: A Phase 1/2, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Chronic Lymphocytic Leukemia
Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Feb;51(2):228-35. doi: 10.3109/10428190903440946.

المؤلفون: Genentech, Inc.

المصدر: A Phase Ib Study of SGN-40 in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Forero-Torres A, Bartlett N, Beaven A, Myint H, Nasta S, Northfelt DW, Whiting NC, Drachman JG, Lobuglio AF, Moskowitz CH. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Feb;54(2):277-83. doi: 10.3109/10428194.2012.710328. Epub 2012 Sep 8.

المؤلفون: Genentech, Inc.

المساهمون: Nancy Whiting, PharmD

المصدر: A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Refractory or Recurrent Multiple Myeloma
Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May;121(4):592-6. doi: 10.1046/j.1365-2141.2003.04322.x.
Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R, Harrop K, Drachman JG, Whiting N. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010 May;95(5):845-8. doi: 10.3324/haematol.2009.008003. Epub 2010 Feb 4.

المؤلفون: Genentech, Inc.

المساهمون: Jonathan Drachman, MD

المصدر: A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma
Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009 Sep 10;27(26):4371-7. doi: 10.1200/JCO.2008.21.3017. Epub 2009 Jul 27.

المؤلفون: Genentech, Inc.

المصدر: A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)

المؤلفون: Weili Xue, Mingzhi Zhang

المصدر: Cancer Biology & Medicine, Vol 18, Iss 1, Pp 52-62 (2021)
Cancer Biology & Medicine

مصطلحات موضوعية: Herpesvirus 4, Human, Cancer Research, molecular targets, medicine.drug_class, medicine.medical_treatment, Review, Antibodies, Monoclonal, Humanized, Monoclonal antibody, lcsh:RC254-282, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, natural killer/t cell lymphoma, medicine, Animals, Humans, Cytotoxic T cell, Brentuximab vedotin, Alemtuzumab, Brentuximab Vedotin, business.industry, Antibodies, Monoclonal, Daratumumab, Dacetuzumab, Immunotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Natural killer T cell, Lymphoma, Lymphoma, Extranodal NK-T-Cell, Oncology, 030220 oncology & carcinogenesis, Cancer research, Natural Killer T-Cells, immunotherapy, business, T-Lymphocytes, Cytotoxic, 030215 immunology, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47ddf4c9f41eea4681c3ab0dd70367bf
https://doi.org/10.20892/j.issn.2095-3941.2020.0400

المؤلفون: Jie Wang, Qing Zeng, Jun Huang

المصدر: BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Cochrane Library, lcsh:RC254-282, law.invention, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Genetics, medicine, Humans, Molecular Targeted Therapy, Network meta-analysis, Lenalidomide, business.industry, Dacetuzumab, Prognosis, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Survival Rate, 030220 oncology & carcinogenesis, Meta-analysis, DLBCL, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, Research Article, 030215 immunology, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11bd9696f6dc5a565913aa7f390f9b4f
https://doaj.org/article/a9a6644aaab54e62899dba57919b18ab

المؤلفون: Atif Sohail, Zabih Warraich, Pavan Tenneti, Ahmad Iftikhar, Faiz Anwer, Adeela Mushtaq, Sandra E. Kurtin, Ali McBride

المصدر: Immunotherapy. 10:265-282

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Immunology, Siltuximab, Atacicept, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Humans, Immunology and Allergy, Isatuximab, business.industry, Lucatumumab, Dacetuzumab, medicine.disease, Milatuzumab, Figitumumab, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Systematic Review, Immunotherapy, Nivolumab, Multiple Myeloma, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61a62ff8651aadca74038879310a7e5d
https://doi.org/10.2217/imt-2017-0136

المؤلفون: Jason Valent, Nathaniel Rosko, Rajshekhar Chakraborty, Hamza Hassan, Abraham S. Kanate, Adeela Mushtaq, Ahmad Iftikhar, Sonia Sandeep, Atif Sohail, Faiz Anwer, Nimra Iftikhar, Faryal Razzaq

المصدر: Antibodies
Antibodies, Vol 8, Iss 2, p 34 (2019)

مصطلحات موضوعية: Oncology, lcsh:Immunologic diseases. Allergy, medicine.medical_specialty, Combination therapy, molecular targets, Immunology, Pembrolizumab, Review, Siltuximab, immune checkpoint inhibitors, chemistry.chemical_compound, Antibody Drug Conjugate, Multiple myeloma, Internal medicine, antibody, Drug Discovery, medicine, Immunology and Allergy, Lenalidomide, Isatuximab, business.industry, Dacetuzumab, Pomalidomide, targeted therapy, Clinical trial, chemistry, immunotherapy, bispecific antibodies, business, lcsh:RC581-607, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57274c873922dd4a9554461aa5e8f709
http://europepmc.org/articles/PMC6640719

المؤلفون: Meletios A. Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Flora Zagouri

المصدر: Expert Opinion on Emerging Drugs. 21:225-237

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Antineoplastic Agents, Pharmacology, Tositumomab, Siltuximab, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Elotuzumab, Isatuximab, business.industry, Lucatumumab, Antibodies, Monoclonal, Dacetuzumab, Daratumumab, Milatuzumab, chemistry, Drug Design, 030220 oncology & carcinogenesis, Quality of Life, Multiple Myeloma, business, 030215 immunology, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5612a8d85123f7eadf9542d6283269b0
https://doi.org/10.1080/14728214.2016.1186644

المؤلفون: Simone Lanini, Bernd Salzberger, Giuseppe Ippolito, Malgorzata Mikulska, Lubos Drgona, Carlota Gudiol

مصطلحات موضوعية: 0301 basic medicine, Microbiology (medical), Consensus, Receptors, CCR4, Gemtuzumab ozogamicin, Sialic Acid Binding Ig-like Lectin 2, Sialic Acid Binding Ig-like Lectin 3, Ki-1 Antigen, Communicable Diseases, Inotuzumab ozogamicin, Lucatumumab, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Signaling Lymphocytic Activation Molecule Family, Daratumumab, Mogamulizumab, Medicine, Humans, Myeloid Cells, Lymphocytes, Molecular Targeted Therapy, Elotuzumab, CD40 Antigens, Brentuximab vedotin, Clinical Trials as Topic, Membrane Glycoproteins, business.industry, Risk of infection, Dacetuzumab, Brentuximab vedotin, Daratumumab, Gemtuzumab ozogamicin, Infection, Inotuzumab ozogamicin, Lucatumumab, Mogamulizumab, Moxetumomab pasudotox, Microbiology (medical), Infectious Diseases, General Medicine, Moxetumomab pasudotox, ADP-ribosyl Cyclase 1, Biological Therapy, 030104 developmental biology, Infectious Diseases, 030220 oncology & carcinogenesis, Immunology, Antigens, Surface, business, Infection, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2efaaee85b2942b8306f1bc8dacbc1a3
http://hdl.handle.net/11567/927134

المؤلفون: Ranjana H. Advani, Andres Forero-Torres, Stephen M. Ansell, Luis Fayad, Bertrand Coiffier, Robert K. Stuart, David Belada, Kazimierz Kuliczkowski, Edmund Ng, Jonathan G. Drachman, Nancy L. Bartlett

المصدر: Leukemia & Lymphoma. 56:2569-2578

مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Prednisolone, Salvage therapy, Kaplan-Meier Estimate, Pharmacology, Antibodies, Monoclonal, Humanized, Carboplatin, chemistry.chemical_compound, Double-Blind Method, immune system diseases, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Ifosfamide, Cyclophosphamide, Etoposide, Aged, Salvage Therapy, business.industry, Remission Induction, Dacetuzumab, Hematology, Middle Aged, medicine.disease, Thrombocytopenia, Treatment Outcome, Cough, chemistry, Doxorubicin, Vincristine, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, Neoplasm Recurrence, Local, business, Diffuse large B-cell lymphoma, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::573868e03282795b5aebe8b4eea330a1
https://doi.org/10.3109/10428194.2015.1007504

المؤلفون: Barbara Nicola Olsen, Jesper Freddie Sørensen, Sufia Butt Hassan, Anders Elm Pedersen

المصدر: Immunopharmacology and Immunotoxicology. 36:96-104

مصطلحات موضوعية: medicine.drug_class, medicine.medical_treatment, Immunology, Toxicology, Monoclonal antibody, Clinical Trials, Phase II as Topic, Cancer immunotherapy, Neoplasms, hemic and lymphatic diseases, medicine, Animals, Humans, Immunology and Allergy, CD40 Antigens, Pharmacology, CD40, Clinical Trials, Phase I as Topic, biology, business.industry, Antibodies, Monoclonal, Cancer, Dacetuzumab, General Medicine, Immunotherapy, medicine.disease, biology.protein, Rituximab, business, Tremelimumab, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ade063298f366efee3aa51ca489ff39e
https://doi.org/10.3109/08923973.2014.890626

المؤلفون: Andres Forero-Torres, Han Myint, Sunita D. Nasta, Nancy L. Bartlett, Nancy Whiting, Albert F. LoBuglio, Anne W. Beaven, Jonathan G. Drachman, Donald W. Northfelt, Craig H. Moskowitz

المصدر: Leukemia & Lymphoma. 54:277-283

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Pilot Projects, Neutropenia, Antibodies, Monoclonal, Humanized, Deoxycytidine, Gastroenterology, Antibodies, Monoclonal, Murine-Derived, Recurrence, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Refractory Diffuse Large B-Cell Lymphoma, Adverse effect, Aged, Aged, 80 and over, business.industry, Dacetuzumab, Hematology, Middle Aged, medicine.disease, Gemcitabine, Lymphoma, Cytokine release syndrome, Treatment Outcome, Oncology, Immunology, Female, Rituximab, Lymphoma, Large B-Cell, Diffuse, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e718ed5b2abe901235015075854754de
https://doi.org/10.3109/10428194.2012.710328

المؤلفون: Mohamad A. Hussein, James R. Berenson, Kate Harrop, Ruben Niesvizky, Nikhil C. Munshi, Jeffrey Matous, Nancy Whiting, Jonathan G. Drachman, Ronald Sobecks

المصدر: Haematologica. 95:845-848

مصطلحات موضوعية: Adult, Male, Pharmacology, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, Cohort Studies, Pharmacokinetics, Humans, Medicine, Dosing, CD40 Antigens, Adverse effect, Multiple myeloma, Aged, Aged, 80 and over, Inflammation, Dose-Response Relationship, Drug, business.industry, Antibodies, Monoclonal, Dacetuzumab, Hematology, Middle Aged, medicine.disease, Clinical trial, Cytokine release syndrome, Monoclonal, Female, Brief Reports, Multiple Myeloma, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc5d1f1fd4676e88fa8e7c76df49279
https://doi.org/10.3324/haematol.2009.008003

المؤلفون: Jonathan G. Drachman, Richard R. Furman, Andres Forero-Torres, Joseph D. Rosenblatt, Kate Harrop, Nancy Whiting, Ranjana H. Advani, Hong Ren, Anas Younes

المصدر: Journal of Clinical Oncology. 27:4371-4377

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Lymphoma, B-Cell, Fever, Anemia, Pleural effusion, Antibodies, Monoclonal, Humanized, Gastroenterology, Cohort Studies, Young Adult, Refractory, Recurrence, Internal medicine, medicine, Humans, CD40 Antigens, Adverse effect, Fatigue, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, business.industry, Lymphoma, Non-Hodgkin, Headache, Antibodies, Monoclonal, Dacetuzumab, Middle Aged, medicine.disease, Lymphoma, Surgery, Treatment Outcome, Oncology, Drug Resistance, Neoplasm, Cohort, Cytokines, Eye disorder, Female, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a671702d23e3d130afbaae007dd04835
https://doi.org/10.1200/jco.2008.21.3017

المؤلفون: Kristine A. Gordon, Zhonghau Lin, Patricia Valdez, Che-Leung Law, Julie A. McEarchern, Charles G. Cerveny, John P. Collier, Alan F. Wahl, Kerry Klussman, Bruce Mixan, Wyne P. Lee, Iqbal S. Grewal

المصدر: Cancer Research. 65:8331-8338

مصطلحات موضوعية: Cancer Research, Lymphoma, B-Cell, medicine.drug_class, Apoptosis, Cell Growth Processes, Mice, SCID, Humanized antibody, Monoclonal antibody, Mice, In vivo, Cell Line, Tumor, otorhinolaryngologic diseases, medicine, Animals, Humans, CD40 Antigens, Cytotoxicity, B-Lymphocytes, CD40, biology, Caspase 3, business.industry, Chinese hamster ovary cell, Antibody-Dependent Cell Cytotoxicity, Antibodies, Monoclonal, Dacetuzumab, Xenograft Model Antitumor Assays, In vitro, Enzyme Activation, Oncology, Caspases, Immunoglobulin G, Immunology, Cancer research, biology.protein, sense organs, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::816456e2fe3b928e7a38c75f3ed4f184
https://doi.org/10.1158/0008-5472.can-05-0095